Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1964 1
1965 4
1967 5
1968 7
1969 3
1970 2
1971 5
1972 8
1973 3
1974 4
1975 5
1976 3
1977 3
1978 1
1979 5
1980 2
1981 1
1982 3
1983 2
1984 6
1985 5
1986 3
1987 1
1988 2
1989 5
1990 3
1991 7
1992 6
1993 10
1994 5
1995 5
1996 4
1997 3
1998 5
1999 6
2000 14
2001 6
2002 9
2003 18
2004 14
2005 10
2006 13
2007 4
2008 10
2009 9
2010 12
2011 16
2012 24
2013 28
2014 28
2015 17
2016 26
2017 19
2018 17
2019 15
2020 16
2021 19
2022 22
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

475 results

Results by year

Filters applied: . Clear all
Page 1
The More Recent History of Hemophilia Treatment.
Franchini M, Mannucci PM. Franchini M, et al. Semin Thromb Hemost. 2022 Nov;48(8):904-910. doi: 10.1055/s-0042-1756188. Epub 2022 Sep 15. Semin Thromb Hemost. 2022. PMID: 36108649 Review.
The availability first in the 1970s of plasma-derived and then in the 1990s of recombinant clotting factor concentrates represented a milestone in hemophilia care, enabling not only treatment of episodic bleeding events but also implementation of prophylactic regime …
The availability first in the 1970s of plasma-derived and then in the 1990s of recombinant clotting factor concentrates represented a …
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E. Ljung R, et al. Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6. Eur J Haematol. 2019. PMID: 30411401 Free PMC article. Review.
The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). ...Bypassing agents can be used to prevent and control bleeding, as well as the recently licensed prophylaxis, emicizu …
The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor …
Diagnosis and treatment of hemophilia.
Kizilocak H, Young G. Kizilocak H, et al. Clin Adv Hematol Oncol. 2019 Jun;17(6):344-351. Clin Adv Hematol Oncol. 2019. PMID: 31437138 Review.
Hemophilia A and B are inherited bleeding disorders characterized by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. ...Another new development, gene therapy, has the potential for a definitive cure. This review summarizes …
Hemophilia A and B are inherited bleeding disorders characterized by deficiency or dysfunction of coagulation protein factors VIII an …
A Molecular Revolution in the Treatment of Hemophilia.
Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. Butterfield JSS, et al. Mol Ther. 2020 Apr 8;28(4):997-1015. doi: 10.1016/j.ymthe.2019.11.006. Epub 2019 Nov 13. Mol Ther. 2020. PMID: 31843450 Free PMC article. Review.
For decades, the monogenetic bleeding disorders hemophilia A and B (coagulation factor VIII and IX deficiency) have been treated with systemic protein replacement therapy. Now, diverse molecular medicines, ranging from antibody to gene to RNA therap …
For decades, the monogenetic bleeding disorders hemophilia A and B (coagulation factor VIII and IX deficiency) have bee …
Pathogenesis and treatment of osteoporosis in patients with hemophilia.
Lin X, Gao P, Zhang Q, Jiang Y, Wang O, Xia W, Li M. Lin X, et al. Arch Osteoporos. 2023 Jan 4;18(1):17. doi: 10.1007/s11657-022-01203-9. Arch Osteoporos. 2023. PMID: 36598583 Free PMC article. Review.
INTRODUCTION: Hemophilia is a rare X-linked recessive inherited bleeding disorder caused by mutations of the genes encoding coagulation factor VIII (FVIII) or IX (FIX). Patients with hemophilia (PWH) often have a high risk of osteoporosis and fractures that is usual …
INTRODUCTION: Hemophilia is a rare X-linked recessive inherited bleeding disorder caused by mutations of the genes encoding coagulation f …
Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Ljung RCR. Ljung RCR. Paediatr Drugs. 2018 Oct;20(5):455-464. doi: 10.1007/s40272-018-0307-z. Paediatr Drugs. 2018. PMID: 30128815 Free PMC article. Review.
Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. ...As the ultimate treatment, recent progr …
Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respect …
Treatment Options in Hemophilia.
Miesbach W, Schwäble J, Müller MM, Seifried E. Miesbach W, et al. Dtsch Arztebl Int. 2019 Nov 22;116(47):791-798. doi: 10.3238/arztebl.2019.0791. Dtsch Arztebl Int. 2019. PMID: 31847949 Free PMC article. Review.
A similar large effect was seen in patients aged 12 to 50 years, with hemorrhage rates of 1.9 (SD 4.1) vs. 28.7 (SD 18.8). Clotting-factor preparations with longer half-lives make it possible to lessen the frequency of administration and to prevent subtherapeutic factor …
A similar large effect was seen in patients aged 12 to 50 years, with hemorrhage rates of 1.9 (SD 4.1) vs. 28.7 (SD 18.8). Clotting-facto …
Primary prophylaxis in haemophilia care: Guideline update 2016.
Fischer K, Ljung R. Fischer K, et al. Blood Cells Mol Dis. 2017 Sep;67:81-85. doi: 10.1016/j.bcmd.2017.02.004. Epub 2017 Feb 17. Blood Cells Mol Dis. 2017. PMID: 28302350 Review.
The dose and dose frequency of prophylaxis is dependent on the goal of treatment, bleeding phenotype, compliance, venous access and economic resources in the health care system and should be tailored individually based on clinical outcome and pharmacokinetics. ...Novel ext …
The dose and dose frequency of prophylaxis is dependent on the goal of treatment, bleeding phenotype, compliance, venous access and economic …
Evolving Complexity in Hemophilia Management.
Croteau SE. Croteau SE. Pediatr Clin North Am. 2018 Jun;65(3):407-425. doi: 10.1016/j.pcl.2018.01.004. Pediatr Clin North Am. 2018. PMID: 29803274 Review.
Rapid expansion of therapeutic options have increased the complexity of hemophilia care. ...The diversity of emerging hemophilia therapies, from modified factor protein concentrates, to gene therapy, to nonfactor hemostatic strategies, provide a …
Rapid expansion of therapeutic options have increased the complexity of hemophilia care. ...The diversity of emerging hemophil …
Definitions in hemophilia: communication from the SSC of the ISTH.
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Blanchette VS, et al. J Thromb Haemost. 2014 Nov;12(11):1935-9. doi: 10.1111/jth.12672. Epub 2014 Sep 3. J Thromb Haemost. 2014. PMID: 25059285 Free article. No abstract available.
475 results